Q1 2025 financial results

Wednesday, May 14

A conference call was hosted at 13:00 CEST / 6 am EDT

To watch the replay, please use the below link

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our science

Latest news

22 May, 2025 Corporate Release
Lundbeck successfully places a EUR 500 million Eurobond
14 May, 2025 Corporate Release
Lundbeck raises financial guidance following strong start to the year with strategic brands growth of +24% CER
08 May, 2025 Press Release
Lundbeck to share pipeline data and key insights into the progression of rare disease, Multiple System Atrophy, at International MSA Congress in Boston

See all news

Come join us in making a difference to patients worldwide.

Job opportunities

Explore the latest financial developments at Lundbeck.

Investors

A better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person and community behind the disease.

Our focus

Our sustainability strategy

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. We remain committed to UN Global Compact Principles, and contribute to seven of the 17 UN Sustainable Development Goals.

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Mara Formentini on working at Lundbeck

Bringing your whole self to work and its rewards

See all stories

Lundbeck at a glance

No health without mental health

Advancing brain health. Transforming lives.